Affiliation:
1. Ben-Gurion University of the Negev,Faculty of Health Sciences,Beer Sheva,Israel,
2. Patanjali Research Institute,Patanjali Herbal Research Department,Haridwar,India,
Abstract
Substantial cohort studies, pre-clinical, clinical trials, and in-depth genomic
and proteomic analysis underlie that several molecular alterations exist in TNBC that
may be favorable or detrimental to cancer progression. Molecular heterogeneity in
TNBC has shortened the disease-free survival rate in response to adjuvant and
neoadjuvant therapies. To determine possible vulnerabilities in TNBC, several drugs
were under investigation. This chapter highlighted the current paradigm of the
therapeutic approach including surgery, radiotherapy, and chemotherapy. In this
review, we also highlighted the clinical trials involved in the management of TNBC by
targeting angiogenesis, apoptosis, androgen receptors, cell cycle, and pro-survival
signalling pathways. To overcome the constraints associated with the mono-therapeutic
approach, pre-clinical and clinical studies of combinational therapy have also been
discussed to improve OS, DFS, and DMFS in TNBC patients. <br>
Publisher
BENTHAM SCIENCE PUBLISHERS